JPRN-UMIN000020222已完成未知
A Phase I Trial of Combined immunotherapy with nivolumab and interferon-beta in Patients with advanced melanoma. - A Phase I Trial of immunotherapy with nivolumab and interferon-beta in melanoma patients.
Tohoku University Graduate School of Medicine0 个研究点目标入组 9 人开始时间: 2015年12月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •hypersensitibity against nivolumab
研究者
相似试验
已完成
1 期
A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancercolorectal cancerJPRN-UMIN000022082Yamaguchi University12
已完成
不适用
The phase I study of the combined immunotherapy using alpha-galactosylceramide pulsed antigen presenting cells and tumor-specific peptide pulsed dendritic cells for patients with advanced head and neck mucosal melanomaHead and neck mucosal malignant melanomaJPRN-UMIN000011508Department of Otorynolaryngology, Head and Neck Surgery9
招募中
2 期
Combined sublingual immunotherapy VALERGEN-DP and VALERGEN-BT-Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000240ational Center of Bioproducts (BIOCEN)120
已完成
1 期
A phase I study of combined immunotherapy using alpha-galactosylceramide pulsed antigen presenting cells and autologous lymphocyte activated by autologous tumor tissue for patients with head and neck squamous cell carcinoma.JPRN-UMIN000009431Graduate School of Medicine, Chiba University, Department of Otorynolaryngology9
进行中（未招募）
不适用
Patients who suffer from T-Prolymphocytic leukemia and have received none or one chemotherapy so far will be treated with Fludarabine, Cyclophosphamide, Mitoxantrone and Alemtuzumab.ntreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL .EUCTR2008-001421-34-DEniversity of Cologne, Sponsor-Quality Management16